Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:08 2024-06-03 EDT			After market 12:21:33
9.035 ^EUR	+4.39%		8.958	-0.85%

05-30	Evotec Partners With French Institutions, Company to Research Obesity	MT
05-30	Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases	MT

EVOTEC : Warburg Research reiterates its Buy rating

May 22, 2024 at 04:09 am

In a research note published by Christian Ehmann, Warburg Research advises its customers to buy the stock. The target price is still set at EUR 18.

Latest news about Evotec SE

Evotec Partners With French Institutions, Company to Research Obesity	05-30	MT
Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases	05-30	MT
Evotec, Inserm, Lille Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases	05-30	CI
Evotec Extends Drug Discovery Collaboration With CHDI Foundation for Huntington's Disease	05-28	MT
Evotec, CHDI Foundation Extend 20-year Partnership for Huntington's Disease Treatments	05-28	MT
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington?s Disease	05-28	CI
EVOTEC : Deutsche Bank maintains a Buy rating	05-23	ZD
Evotec Shares Rise Following Gene Therapy Exit, Q1 Results	05-22	MT
EVOTEC : RBC gives a Buy rating	05-22	ZD
Transcript : Evotec SE, Q1 2024 Earnings Call, May 22, 2024	05-22
Evotec Q1 Net Loss Widens as Revenue Falls	05-22	MT
Uncertainty at Evotec hampers share price performance	05-22	DP
Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2024	05-22	CI
EVOTEC : Warburg Research reiterates its Buy rating	05-22	ZD
EVOTEC : Jefferies keeps its Buy rating	05-22	ZD
Evotec remains under pressure - 'Too many question marks'	05-22	DP
EVOTEC : Gets a Buy rating from RBC	05-22	ZD
Jefferies lowers target for Evotec to 16 Euro - 'Buy'	05-20	DP
EVOTEC : Jefferies maintains a Buy rating	05-20	ZD
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment	05-14	MT
Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease	05-14	CI
EVOTEC : Warburg Research reiterates its Buy rating	05-06	ZD
EVOTEC : RBC reiterates its Buy rating	05-03	ZD
Bayer: strategic collaboration with Evotec	04-30	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	04-30	MT

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Jefferies Global Healthcare Conference

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.655 EUR

Average target price

20.79 EUR

Spread / Average Target

+140.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-57.54%	1.66B
MODERNA, INC.	+46.11%	54.63B
IQVIA HOLDINGS INC.	-6.94%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+13.34%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.73%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.86%	12.21B
BIO-TECHNE CORPORATION	+0.63%	12.16B
MEDPACE HOLDINGS, INC.	+25.80%	11.94B

Other Biotechnology & Medical Research

Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

EVOTEC : Warburg Research reiterates its Buy rating

Latest news about Evotec SE

Chart Evotec SE

Company Profile

Income Statement Evolution

Ratings for Evotec SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research